Medicenna Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	2018 - 2014
Net Income	-25.47	-25.47	-10.05	-22.58	-17.29	-8.28	Upgrade
Depreciation & Amortization	0	0	0	0.04	0.04	0.01	Upgrade
Depreciation & Amortization, Total	0	0	0	0.04	0.04	0.01	Upgrade
Stock-Based Compensation	1.21	1.21	1.37	1.42	1.01	1.13	Upgrade
Other Operating Activities	7.25	7.25	-6.39	-0.62	0.25	2.52	Upgrade
Change in Accounts Receivable	1.68	1.68	1.23	-0.39	-1.61	0.14	Upgrade
Change in Accounts Payable	-0.94	-0.94	1.18	-1.45	2.29	-0.93	Upgrade
Operating Cash Flow	-16.26	-16.26	-12.66	-23.58	-15.31	-5.42	Upgrade
Investment in Securities	-	-	-	10.05	5.01	-15	Upgrade
Investing Cash Flow	-	-	-	10.05	5.01	-15	Upgrade
Long-Term Debt Repaid	-	-	-	-0.04	-0.04	-0	Upgrade
Total Debt Repaid	-	-	-	-0.04	-0.04	-0	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0.04	-0.04	-0	Upgrade
Issuance of Common Stock	-	-	24.76	3.92	18.3	40.75	Upgrade
Financing Cash Flow	-	-	24.76	3.88	18.26	40.75	Upgrade
Foreign Exchange Rate Adjustments	-0.35	-0.35	0.96	-0.18	-0.28	-0	Upgrade
Net Cash Flow	-16.61	-16.61	13.06	-9.84	7.68	20.33	Upgrade
Free Cash Flow	-16.26	-16.26	-12.66	-23.58	-15.31	-5.42	Upgrade
Free Cash Flow Per Share	-0.23	-0.23	-0.20	-0.43	-0.31	-0.17	Upgrade
Levered Free Cash Flow	-2.78	-2.78	-4.41	-15.14	-9.15	-2.05	Upgrade
Unlevered Free Cash Flow	-2.78	-2.78	-4.41	-15.14	-9.15	-2.05	Upgrade
Change in Net Working Capital	-7.68	-7.68	-4.41	2.54	-0.68	-1.97	Upgrade

Source: S&P Capital IQ. Standard template.